Literature DB >> 31069832

Plasma metabolite biomarkers related to secondary hyperparathyroidism and parathyroid hormone.

Qixia Shen1,2,3,4,5, Wenyu Xiang1,2,3,4,5, Sen Ye1,2,3,4,5, Xin Lei1,2,3,4,5, Lefeng Wang1,2,3,4,5, Sha Jia1,2,3,4,5, Xue Shao1,2,3,4,5, Chunhua Weng1,2,3,4,5, Xiujin Shen1,2,3,4,5, Yucheng Wang1,2,3,4,5, Shi Feng1,2,3,4,5, Lihui Qu1,2,3,4,5, Cuili Wang1,2,3,4,5, Jianghua Chen1,2,3,4,5, Ping Zhang1,2,3,4,5, Hong Jiang1,2,3,4,5.   

Abstract

BACKGROUND: Hyperphosphatemia, hypocalcemia, and elevation of parathyroid hormone (PTH) are typical abnormalities of uremic patients with Secondary hyperparathyroidism (SHPT). However, metabolic imbalance associated with SHPT is not well understood.
METHODS: A total of 15 SHPT patients with an intact parathyroid hormone (iPTH) level > 600 pg/mL were set as preoperative (PR) group, 15 age- and gender-matched controls who had undergone parathyroidectomy plus forearm transplantation because of hyperparathyroidism and achieved an iPTH level <150 pg/mL were set as postoperative (PO) group. Metabolite profiling of these 30 uremic patients and five healthy controls (HC) was performed using ultra performance liquid chromatography-mass spectrometry.
RESULTS: Five differential metabolites, including allyl isothiocyanate, L-phenylalanine, D-Aspartic acid, indoleacetaldehyde, and D-galactose correlated with PTH were identified in this study. Taking them as a biomarker signature, PR group can be distinguished from HC group with an area under the curve (AUC) of 0.947 (95% CI, 0.76-1) and PO group with an AUC of 0.6 (95% CI, 0.38-0.807).
CONCLUSIONS: The serum metabolome correlated with PTH is successfully demonstrated for a better understanding of the pathogenesis of SHPT.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  end-stage renal disease; long-term dialysis; metabolites; parathyroid hormone; secondary hyperparathyroidism

Mesh:

Substances:

Year:  2019        PMID: 31069832     DOI: 10.1002/jcb.28846

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  2 in total

1.  Application of nanocarbon negative imaging technology in surgery for secondary hyperparathyroidism.

Authors:  Yu Wu; Ying Liu; Tao Huang; Yasu Jiang; Hua Wang; Zhixian He
Journal:  Gland Surg       Date:  2021-08

2.  Introducing Serine as Cardiovascular Disease Biomarker Candidate via Pathway Analysis.

Authors:  Mostafa Rezaei Tavirani; Mona Zamanian Azodi; Mohammad Rostami-Nejad; Hamideh Morravej; Zahra Razzaghi; Farshad Okhovatian; Majid Rezaei-Tavirani
Journal:  Galen Med J       Date:  2020-02-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.